Baseline characteristics of the ITP patients with platelet responses to rituximab
| . | Adults . | Children . | Adults sustaining responses without relapsing . | Children sustaining responses without relapsing . |
|---|---|---|---|---|
| No. of patients | 72 | 66 | 46 | 32 |
| Median age, y (range)* | 39 (18-78) | 12 (2-17) | 35 (18-78) | 13 (2-17) |
| Female sex, n (%) | 47 (65) | 40 (61) | 29 (63) | 21 (66) |
| Median duration of ITP (range) | 3 y (1 mo-39 y) | 20 mo (1 mo-9 y) | 3 y (1 mo-39 y) | 20 mo (1 mo-9 y) |
| Splenectomized, n (%) | 23 (32) | 10 (15) | 13 (28) | 4 (13) |
| Type of initial response, n (%) | ||||
| Complete response (%) | 55 (76) | 45 (68) | 38 (83) | 26 (81) |
| Partial response (%) | 17 (24) | 21 (32) | 8 (17) | 6 (19) |
| . | Adults . | Children . | Adults sustaining responses without relapsing . | Children sustaining responses without relapsing . |
|---|---|---|---|---|
| No. of patients | 72 | 66 | 46 | 32 |
| Median age, y (range)* | 39 (18-78) | 12 (2-17) | 35 (18-78) | 13 (2-17) |
| Female sex, n (%) | 47 (65) | 40 (61) | 29 (63) | 21 (66) |
| Median duration of ITP (range) | 3 y (1 mo-39 y) | 20 mo (1 mo-9 y) | 3 y (1 mo-39 y) | 20 mo (1 mo-9 y) |
| Splenectomized, n (%) | 23 (32) | 10 (15) | 13 (28) | 4 (13) |
| Type of initial response, n (%) | ||||
| Complete response (%) | 55 (76) | 45 (68) | 38 (83) | 26 (81) |
| Partial response (%) | 17 (24) | 21 (32) | 8 (17) | 6 (19) |
ITP indicates immune thrombocytopenic purpura.
Children were included starting at the time of their response whereas adults were only included if their response duration was at least 1 year. This minimally biases the results of the median age towards an increased age at 1 year because children who relapse during the first year are removed but no adults are removed.